While single-agent treatments effectively inhibited tumor growth, the combined dPEDE-A@M32 and anti-PD-1 therapy significantly enhanced therapeutic outcomes in BC mice (Figure 7G-I). This evidence concerns the gene PDCD1 and breast cancer.